MA38687A1 - Composition pharmaceutique, préparation et utilisations de celle-ci - Google Patents

Composition pharmaceutique, préparation et utilisations de celle-ci

Info

Publication number
MA38687A1
MA38687A1 MA38687A MA38687A MA38687A1 MA 38687 A1 MA38687 A1 MA 38687A1 MA 38687 A MA38687 A MA 38687A MA 38687 A MA38687 A MA 38687A MA 38687 A1 MA38687 A1 MA 38687A1
Authority
MA
Morocco
Prior art keywords
compound
interest
pharmaceutical composition
subject
preparation
Prior art date
Application number
MA38687A
Other languages
English (en)
Inventor
Agnes Pottier
Laurent Levy
Marie Edith Meyre
Audrey Darmon
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA38687A1 publication Critical patent/MA38687A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant la combinaison de (i) une nanoparticule biocompatible et de (ii) un composé pharmaceutique d'intérêt, à administrer à un sujet dans le besoin d'un tel composé d'intérêt, où les nanoparticules potentialisent le composé d'efficacité intéressante. La dimension la plus longue de la nanoparticule biocompatible est typiquement entre environ 4 et environ 500 nm, et sa valeur de charge de surface absolue est d'au moins 10 mv (|10 m v|). L'invention concerne aussi une telle composition pour l'administration du composé d'intérêt à un sujet dans le besoin de celui-ci, où la nanoparticule et le composé d'intérêt doivent être administrés audit sujet entre plus de 5 minutes et environ 72 heures l'un de l'autre.
MA38687A 2013-05-30 2014-05-30 Composition pharmaceutique, préparation et utilisations de celle-ci MA38687A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305712 2013-05-30
PCT/EP2014/061296 WO2014191569A1 (fr) 2013-05-30 2014-05-30 Composition pharmaceutique, préparation et utilisations de celle-ci

Publications (1)

Publication Number Publication Date
MA38687A1 true MA38687A1 (fr) 2017-12-29

Family

ID=48656009

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38687A MA38687A1 (fr) 2013-05-30 2014-05-30 Composition pharmaceutique, préparation et utilisations de celle-ci

Country Status (17)

Country Link
US (2) US10413509B2 (fr)
EP (1) EP3003288A1 (fr)
JP (1) JP6387400B2 (fr)
KR (1) KR102245421B1 (fr)
CN (2) CN112107558A (fr)
AU (1) AU2014273043B2 (fr)
BR (1) BR112015029853A2 (fr)
CA (1) CA2913023C (fr)
EA (1) EA038671B1 (fr)
HK (1) HK1222563A1 (fr)
MA (1) MA38687A1 (fr)
MX (1) MX376269B (fr)
NZ (1) NZ714273A (fr)
SG (1) SG11201509436TA (fr)
UA (1) UA116380C2 (fr)
WO (1) WO2014191569A1 (fr)
ZA (1) ZA201509307B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6042450B2 (ja) 2011-12-16 2016-12-14 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
PL2948179T3 (pl) 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
MA38687A1 (fr) * 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
AU2015352685B2 (en) * 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
WO2016134134A1 (fr) * 2015-02-19 2016-08-25 Carnegie Mellon University Méthodes de diminution des toxicités et d'amélioration des biodisponibilités de nanomédicaments
JP2018516256A (ja) 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
CN105055447B (zh) * 2015-06-23 2018-03-13 中南大学湘雅二医院 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用
CA3104664A1 (fr) * 2018-06-29 2020-01-02 North Carolina State University Gel immunotherapeutique biosensible pulverise in situ pour un traitement post-chirurgical
CN108969757B (zh) * 2018-07-11 2021-07-27 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN110498607B (zh) * 2019-08-21 2022-03-08 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US20030186869A1 (en) * 1990-05-14 2003-10-02 George Poiani Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
DE69819519T2 (de) 1997-08-19 2004-09-23 Warner-Lambert Co. Llc Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
EP1299085B1 (fr) * 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Compositions ameliorees de camptothecines dans des liposomes et leurs applications
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (fr) * 2003-12-22 2013-12-17 Bracco Research Sa Systeme de microvesicule remplie de gaz pour l'imagerie de contraste
WO2005086639A2 (fr) 2004-02-10 2005-09-22 Barnes-Jewish Hospital Efficacite et securite ameliorees d'agents particulaires diriges a l'aide de systemes leurres
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (fr) 2006-03-24 2007-11-01 Toto Ltd. Particules complexes d'oxyde de titane, dispersion des particules et procédé pour la production des particules
JP2009536151A (ja) * 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
JP2009536162A (ja) 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
CA2697042A1 (fr) 2007-08-21 2009-02-26 Alza Corporation Compositions a base de liposomes pour une administration in vivo de composes d'acide boronique
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009081287A2 (fr) * 2007-12-21 2009-07-02 University Of Guelph Nanoparticules de polysaccharide
CA2716347C (fr) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Inhibiteurs aminoacides du cytochrome p450
WO2009142754A1 (fr) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugués dendritiques et procédés associés
EP2130553A1 (fr) 2008-06-05 2009-12-09 Nanobiotix Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
US20130023714A1 (en) * 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2275137A1 (fr) * 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US9255259B2 (en) * 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
CA3051495A1 (fr) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Utilisation de nanoparticules comprenant une taxane et une albumine pour le traitement de carcinome hepatocellulaire
GB201009455D0 (en) * 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (fr) 2010-10-11 2012-04-19 Wichita State University Système de délivrance de médicaments de nanoparticules magnétiques composites
RU2013117288A (ru) 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
CN103429227B (zh) 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
EP2670393B8 (fr) 2011-01-31 2016-10-05 Nanobiotix Procédé de surveillance de la libération par des liposomes d'un produit d'intérêt au moyen de nanoparticules superparamagnétiques
US20120237566A1 (en) * 2011-03-15 2012-09-20 Venture Isles, LLC Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use
WO2013059295A2 (fr) 2011-10-17 2013-04-25 Trustees Of Boston University Dépôts polymères pour la localisation d'un agent à des sites biologiques
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (fr) 2012-09-07 2014-03-13 Carnegie Mellon University Procédés et matériel pour réduire la clairance de particules d'un sujet par le système réticuloendothélial
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
MA38687A1 (fr) 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
EP2886128A1 (fr) 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
WO2016083336A1 (fr) 2014-11-25 2016-06-02 Nanobiotix Composition pharmaceutique, sa préparation et ses utilisations

Also Published As

Publication number Publication date
UA116380C2 (uk) 2018-03-12
US10413509B2 (en) 2019-09-17
US11357724B2 (en) 2022-06-14
JP6387400B2 (ja) 2018-09-05
CN105407878A (zh) 2016-03-16
MX2015016456A (es) 2016-03-03
SG11201509436TA (en) 2015-12-30
MX376269B (es) 2025-03-07
AU2014273043B2 (en) 2019-02-07
EP3003288A1 (fr) 2016-04-13
EA201592279A1 (ru) 2016-06-30
KR102245421B1 (ko) 2021-04-29
WO2014191569A1 (fr) 2014-12-04
AU2014273043A1 (en) 2015-12-03
ZA201509307B (en) 2017-04-26
HK1222563A1 (zh) 2017-07-07
BR112015029853A2 (pt) 2017-07-25
KR20160013212A (ko) 2016-02-03
CA2913023A1 (fr) 2014-12-04
US20200009050A1 (en) 2020-01-09
CN112107558A (zh) 2020-12-22
NZ714273A (en) 2019-04-26
EA038671B1 (ru) 2021-10-01
CA2913023C (fr) 2021-06-08
JP2016522833A (ja) 2016-08-04
US20160184225A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
EA201592279A1 (ru) Фармацевтическая композиция, ее получение и применение
El Morsy et al. Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats
MA45972B1 (fr) Unité posologique orodispersible contenant un composant d'estétrol
UY30100A1 (es) Una formulacion farmacéutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
EA200501203A1 (ru) Жидкие фармацевтические композиции палоносетрона
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MX2017006812A (es) Composición farmacéutica, preparación y usos de la misma.
AR046601A1 (es) Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
Braga et al. Comparison of the effects of pilocarpine and cevimeline on salivary flow
FR2977723B1 (fr) Matiere active d'electrode pour une batterie aux ions sodium
SV2017005595A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
WO2006124698A3 (fr) Traitement au dronabinol de nausees et vomissements induits par chimiotherapie differee
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
MA35111B1 (fr) Formulation de capsule à double libération de composés constituée de bromodihydroartémisinine et d'un agent de fe2+
EP2525819A4 (fr) Compositions d'immunothérapie et procédés de traitement
WO2016014680A8 (fr) Compositions transmucosales orales comprenant des inhibiteurs d'aromatase pour lutter contre les faibles taux de testostérone chez les hommes
Orlandi et al. Tacrolimus-associated myositis: a case report in a renal transplant patient
JP2013533304A5 (fr)
Fatani et al. Comparative study between the protective effects of Saudi and Egyptian antivenoms, alone or in combination with ion channel modulators, against deleterious actions of Leiurus quinquestriatus scorpion venom